<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Prior studies have investigated patients' characteristics, treatments, and outcomes for older adults with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, but most failed to distinguish <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recognizing potentially important differences between the diseases, we undertook a population-based comparison of baseline characteristics, treatments, and outcomes between older adults with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The patients' data were obtained from Surveillance Epidemiology and End Results registry data from 2001-2005, linked to Medicare claims </plain></SENT>
<SENT sid="3" pm="."><plain>Baseline characteristics, treatment (red blood cell transfusions, hematopoietic growth factors, hypomethylating agents, chemotherapy or transplantation), progression to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, and overall survival were compared using bivariate techniques </plain></SENT>
<SENT sid="4" pm="."><plain>Multivariate logistic regression estimated differences in treatments received </plain></SENT>
<SENT sid="5" pm="."><plain>Cox proportional hazard models estimated the effects of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> relative to <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> on progression-free survival </plain></SENT>
<SENT sid="6" pm="."><plain>A larger proportion of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n=792), compared to patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (n=7,385), failed to receive any treatment (25% versus 15%; P&lt;0.0001), or only received red blood cell transfusions (19.8% versus 16.7%; P=0.037) </plain></SENT>
<SENT sid="7" pm="."><plain>A larger percentage of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> progressed to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (42.6% versus 15.5%, respectively; P&lt;0.0001), with shorter time to progression </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients had a shorter median survival (13.3 versus 23.3 months; P&lt;0.0001) and lower 3-year survival rate (19% versus 36%; P&lt;0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>Adjusted estimates, controlling for baseline characteristics and selected treatments, indicate that <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> was associated with an increased risk of progression to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> or <z:hpo ids='HP_0011420'>death</z:hpo> (HR 2.22; P&lt;0.0001), compared to <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> is less frequently treated in older adults and is associated with worse outcomes, even after controlling for the patients' baseline characteristics and selected treatments </plain></SENT>
<SENT sid="11" pm="."><plain>Our data suggest the need for continued evaluation of the biological differences between these diseases and clinical trials targeting <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>